Clinical trials: Localized Adverse Reaction to Administration of Drug

Localized Adverse Reaction to Administration of Drug

Intralymphatic eASC Administration in Healthy Volunteers

• Completed
• Age: 18 to 55 years
• Phase 1

The objective is to determine the safety, tolerability and feasibility of the inguinal intralymphatic administration of expanded allogeneic adipose-derived stem cells (eASCs)

Trial name

NCT01743222

Testing

eASC

Where

Spain

Volunteers

10 people, healthy volunteers welcome

Sponsor

Tigenix S.A.U.